News | Remington Davis

The Dynamics of Dermatology Clinical Trials: From New Therapies to Patient Enrollment

Jun 20th, 2024 in News

Dr. Michelle Chambers, a Remington-Davis (RDI) board certified dermatologist, has been involved in dermatological clinical research since the 1990s — she brought her expertise to Remington-Davis in 2019. We recently had the chance to sit down with Dr. Chambers and look at some[...]

Remington-Davis Welcomes Dr. Roy St. John to Its Physician Team

May 30th, 2024 in News

We are excited to announce the new addition to the Remington-Davis family: Dr. Roy St. John. He joins our team of expert board-certified physicians in the central Ohio region that represent over 20 therapeutic areas, including pulmonology. As a board-certified Pulmonary &[...]

Beyond Enrollment: How Site Selection Impacts Patient Retention in Clinical Trials

May 20th, 2024 in News

Patient recruitment is recognized as one of the biggest challenges in clinical research. But getting patients enrolled in clinical trials is just the first step — it then becomes a question of how to keep them engaged in the process. And as research shows, this is easier said[...]

eSource for Clinical Trials: Exploring Challenges & Opportunities

May 6th, 2024 in News

eSource — the electronic capture of clinical trial source data — first gained traction in the late 2000s as technologies like electronic health records (EHRs) and electronic patient diaries became more prevalent. Designed to replace the manual collection and entry of data, the[...]

Applying the Benefits of Decentralized Clinical Trials to Hybrid Trials

Apr 22nd, 2024 in News

The pandemic was a clear catalyst in the rise of decentralized clinical trials (DCTs). But it may come as a surprise to some that this shift from traditional clinical trials was already gaining momentum in the years prior with advancements in technology. Telemedicine platforms,[...]

Advancements in Respiratory Medicine: An Interview With Dr. Edward Cordasco

Apr 15th, 2024 in News

Respiratory medicine is continuously evolving, with new advancements taking shape to support progress and better outcomes every day. We recently discussed some of these advancements with Dr. Edward Cordasco, a Remington-Davis (RDI) board-certified physician with over 36 years of[...]

Diversity in Clinical Trials: The Latest FDA Guidance

Feb 21st, 2024 in News

Diversity has always mattered in clinical trials and health care in general. As the National Institutes of Health (NIH) notes, “people may experience the same disease differently.” With a more diverse pool of clinical trial participants, researchers can better account for these[...]

Why Is It So Hard To Find Healthy Volunteers for Clinical Trials?

Jan 23rd, 2024 in News

Healthy volunteers are a cornerstone of successful clinical trials. Before medications or devices are given to patient groups with a specific condition, interventions on healthy volunteers set a baseline in the early stages of clinical research. These control groups ultimately[...]

Trends in Immunology Clinical Trials: An Interview With Dr. Ian Baird

Jan 17th, 2024 in News

The landscape of immunology clinical trials rarely stands still, from breakthroughs in scientific advancements to changing outlooks on trial dynamics and expectations. Dr. Ian Baird, a Remington-Davis (RDI) board-certified infectious disease physician who has conducted 262[...]

Two OSU nursing students take part in clinical trials that might help battle COVID-19

Jul 31st, 2020 in News

Here’s your chance to catch up on a story featuring two #OSUNursing students who #volunteered for a #clinicaltrial with #RemingtonDavis when they contracted #Covid_19. [...]

Remington-Davis launches dedicated COVID-19 research unit in Ohio

Jul 8th, 2020 in News

By Chris Newmarker | July 8, 2020 Clinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials. The space includes six private overnight rooms, patient lounge, dedicated laboratory,[...]

hubspot: